Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a ...
The reduced monthly HAE attack rate was maintained for at least 1.5 years in the CHAPTER-1 OLE study. What improvements did participants report in the CHAPTER-1 OLE study? All participants ...
Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in ...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31 ...
The following is a summary of “Novel Bradykinin Detection In The Diagnostic Workup Of Patients With Recurrent Angioedema ...
“The growing body of data from the KONFIDENT-S study consistently demonstrate that sebetralstat enabled early treatment and fast symptom relief from HAE attacks, regardless of age, attack ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results